Peter Hall

Clinical Senior Lecturer in Cancer Informatics and Health Economics

  • Cancer Research UK Edinburgh Centre
  • MRC Institute of Genetics & Molecular Medicine
  • [Clinical practice - Edinburgh Cancer Centre, Western General Hospital, NHS Lothian]

Contact details

Address

Street

Cancer Research UK Edinburgh Centre
MRC Institute of Genetics & Molecular Medicine
The University of Edinburgh
Western General Hospital
Crewe Road South

City
Edinburgh
Post code
EH4 2XR
Street

PA : laura.wood@ed.ac.uk

City
Post code

Availability

  • Mon - Edinburgh Cancer Research Centre
    Tue - Edinburgh Bioquarter
    Wed - NHS Lothian, St John's Hospital
    Thur - NHS Lothian, Western General Hospital
    Fri - Edinburgh Cancer Research Centre

Background

Dr Peter Hall is an academic Medical Oncologist with a research interest in Health Economics and Health Technology Assessment in Cancer. He treats patients with breast cancer within the NHS at the Edinburgh Cancer Centre.

He graduated from the University of Edinburgh Medical School in 2003, undertaking general medical training in Fife and Dundee. He commenced specialist training in Medical Oncology with the Yorkshire Deanery in 2006. He undertook at NICE scholarship in 2007. He completed a PhD in Health Economics and Clinical Trial design at the University of Leeds in 2012. In 2014 he took up his current position in Edinburgh.

The focus of his research is on the development of improved methods for efficient research design, cost-effectiveness analysis and the measurement of clinical and socioeconomic outcomes using data obtained from clinical trials and routinely collected within the NHS. 

He leads the Health Economics Group within the University of Edinburgh Clinical Trials Unit. He has been a NICE Appraisal Committee member since 2017. He is a Visiting Associate Professor of Health Economics at the Academic Unit of Health Economics, University of Leeds .

Publications on Google Scholar 

ORCID ID 0000-0001-6015-7841 

Scopus Author ID: 7403693888

Research Gate

Personal academic web repository

Qualifications

MB ChB, MRCP, PhD

Responsibilities & affiliations

Health Economics Group Lead, Edinburgh Clinical Trials Unit.

Vice-Chair, NHS Lothian Cancer Informatics Programme

Technology Appraisal Committee Member, National Institute for Health and Care Excellence (NICE)

Postgraduate teaching

We run an annual 5 day course Cost-effectiveness Modelling course in collaboration with the Universities of Leeds, Aukland and Alberta which is supported by our contemporary textbook:

For training on the use of the R statistical programming package enrole on the HealthR course http://healthyr.surgicalinformatics.org/

Problem Solving in Oncology Series:

Current PhD students supervised

Katie Spencer (University of Leeds, PhD) http://medhealth.leeds.ac.uk/profile/600/1790/dr_katie_spencer

Alison Smith (University of Leeds, PhD) http://medhealth.leeds.ac.uk/profile/600/1268/alison_f._smith/4

Agastya Silvina (University of St Andrews, EngD)

Robert Nagy              "Methods for Budget Impact Analysis for for new cancer medicines"

Giovanni Tramonti "Cost-effectiveness of pre- and on-treatment molecular testing for neoadjuvant therapy in early breast cancer"

Kenneth Haining     "Socioeconomic outcomes measurement in survivors of major illness using public sector data"

 

Research summary

Our research programme is cross-disciplinary and resides at the interface between Cancer Research, Health Economics and Clinical Trials Research. Our aspiration is to improve clinical outcomes for the cancer population and we undertake research to provide robust evidence for the real-world evaluation of new interventions for cancer. The focus of our research includes:

  • Economic evaluation of new interventions for cancer
  • Bayesian decision analysis for efficient research design
  • Economic evaluation of biomarkers and personalised medicine strategies
  • The use of routine NHS data through clinical informatics to measure the costs of care
  • Methods for the measurement of the financial burden of cancer on patients and carers
  • Outcomes measurement in elderly and non-trial-eligible cancer patients

 Read about Real World Data for HTA   

We maintain the development of the "UK Cancer Costs Questionnaire" as a tool to measure economic and cost endpoints in clinical trials, and the composite cancer outcomes measure "Overall Treatment Utility".

The Scottish Cancer Innovation Challenge is a £1M project funded by the Scottish Funding Council (SFC) to encourage Innovation Centres in Scotland to work in partnership to help Scotland become a world leading carer for people with cancer through open innovation funding calls for data science solutions.

Project activity

Real-World Data and Informatics Projects

  • SATURNE     A natural experiment using Scottish clinical data to estimate the real-world effectiveness of adjuvant chemotherapy in breast cancer patients.(CSO HIPS/16/26)
  • CORECT-R    Our health economics workstream is creating a comprehensive UK-wide linked healthcare data resource for bowel cancer researchers who wish to study costs and economic aspects of bowel cancer (CRUK). Read about CORECT-R on the Bowel Cancer Intelligence website
  • The Allocative Efficiency in End of Life Care project is an econometrics collaboration between England, Scotland and Switzerland. We are study the efficient allocation of budgetary resource between health and social care sectors. Details on the Health Foundation website.
  • The use of comprehensive patient records (CPR) to define the impact of cancer, co-morbidities and late effects on individuals and the health service - a MacMillan funded project based in Leeds.

Clinical Trials and Cost-effectiveness analysis

  • OPTIMA   Early breast cancer clinical trial is studying the effectiveness and cost-effectiveness of new genomic tests that may help women decide whether chemotherapy is the right choice for them after curative surgery.  OPTIMA on the NIHR HTA webpage
  • MAMMO-50  A multi-centre, randomised, controlled, phase III trial of annual mammography versus 2 yearly for conservation surgery patients and 3 yearly for mastectomy patients. Mammo-50 on the NIHR HTA webpage
  • PERSEPHONE - duration of trastuzumab study with chemotherapy in early breast cancer: six versus twelve months. Persephone on the NIHR HTA webpage
  • GO-2     Chemotherapy options for frail and elderly patients with advanced gastro-esophageal cancer: A UK Randomised controlled trial. CRUK The GO-2 trial 
  • c-TRAK-TN  ctDNA to Detect Cancer Cells After Standard Treatment to Trigger Immunotherapy in Early Stage Triple Negative Breast Cancer Patients c-TRAK-TN
  • ACUFOCIN  Randomised controlled trial of acupuncture plus standard care versus standard care for chemotherapy induced peripheral neuropathy (CIPN).2 NIHR Research for Patient Benefit, incollaboration with the Christie Clinical Trials Unit, Manchester.
  • EMT2  Omega-3 fatty acid (EPA) after liver resection surgery for colorectal cancer metastasis . Yorkshire Cancer Research. The EMT2 study.
  • ENeRgy  Exercise and Nutritional Rehabilitation in patients with advanced cancer, with Marie Fallon and Barry Laird

  • CardiacCARE  Cardiac protection during adjuvant chemotherapy for early breast cancer, initiated by Troponin I. EME - 15/48/20

 

Past project grants

SABRTOOTH  A study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic Ablative Radiotherapy (SABR) with surgery in paTients with peripheral stage I nOn-small cell lung cancer (NSCLC) cOnsidered To be at Higher risk of complications from surgical resection. NIHR Research for Patient Benefit

The future for diagnostic tests for acute kidney injury in critical care: Evidence synthesis, care pathway analysis and research prioritisation “AKI-Diagnostics” 2014-2016 NIHR Health Technology Assessment (Chief Investigator) (Hall P, Lewington A et al. ) https://www.journalslibrary.nihr.ac.uk/programmes/hta/1311613#/

2007-2009 Cancer Research UK (Feasibility studies committee)(Seymour M, Hall P, Lord S et al.) With additional £30,000 Roche educational grant. “321GO”: Three, two or one drug chemotherapy for advanced gastroesophageal (GO) cancer: a feasibility study in frail and/or elderly patients.

2013 ePOCs project (economic analysis component) Subcontracted from MacMillan research grant. Wright et al. Electronic patient reported outcomes from cancer survivors.

2013-2015 NIHR (Health Technology Assessment)(Stein R, et al.) “Optimal personalised treatment of breast cancer using multi-parameter analysis (OPTIMA)”.

2015-2017 NHS England Research Innovation fund. (Hall G, et al). In partnership with Caris Life Sciences International. Pilot study to assess feasibility of tumour profiling for solid tumour cancer patients in the NHS.

2013-14 Technology Strategy Board Small Business Research Initiative. Detection and Identification of infectious agents: Assessing the impact of near patient testing. Network Tools for Intervention Modelling In Sepsis. X-Lab Ltd.

2013-16 Technology Strategy Board Small Business Research Initiative £1.8m, Development of a home monitoring device for neutropenia. Phillips.

View all 90 publications on Research Explorer

More video

In the press

Is accelerating drug trials a good idea? 

Acceleration of drug trials offers the potential to bring life-prolonging treatments to patients more quickly, but some physicians warn that research risks being dumbed down. These issues are discussion in the Financial Times special edition Raconteur supplement  https://www.raconteur.net/healthcare/accelerating-drug-trials

The Edinburgh Health Economics Group supports the work of the Edinburgh Clinical Trials Unit and maintains its own research portfolio. The focus of our expertise is on methods for the us of real world data in addition to clinical trials research to inform Health Technology Assessment. 

Current team members:

John Norrie, Chris Wier, Lorraine Smith and Pamela Sinclair provide senior statistical, operational and administrative support.